Characterising inflammatory markers in two childhood autoimmune diseases (JIA and JDM) pre and post methotrexate by Ursu, S et al.
ORAL PRESENTATION Open Access
Characterising inflammatory markers in two
childhood autoimmune diseases (JIA and JDM)
pre and post methotrexate
S Ursu
*†, H Moncrieffe
†, H Varsani, RHB Hamaoui, L Beard, L Kassoumeri, F Patrick, LR Wedderburn
From 18th Pediatric Rheumatology European Society (PReS) Congress
Bruges, Belgium. 14-18 September 2011
Background
Methotrexate (MTX) is the first line of therapy for
patients with juvenile idiopathic arthritis (JIA) and juve-
nile dermatomyositis (JDM). The mechanisms of action
of MTX in childhood autoimmunity are not fully eluci-
dated. The primary target sites of inflammation of JIA
and JDM i.e. joint and muscle, respectively do not repre-
sent sites from which samples can be easily obtained to
monitor inflammatory markers. In contrast peripheral
blood is accessible and can be obtained at time of rou-
tine clinical screen. We hypothesized that changes in
peripheral blood of patients would be informative in
monitoring disease and understanding inflammatory
pathways that are modulated by MTX.
Aim
To characterise the inflammatory immunological profile
at protein and cellular level in peripheral blood of
patients with JIA and JDM pre and post MTX.
Methods
Blood samples and clinical data were obtained from 109
JIA patients from the Sparks CHARM study and 27
JDM patients from the UK JDM Cohort study pre and
at 6 months of therapy and 6 healthy control children.
The study had full ethical approval and consent. Nine
serum cytokines including TNF-alpha and IL-1beta were
quantified by in-house Luminex (de Jager, 2007). PBMC
were extracted by standard density centrifugation and
intracellular cytokines measured by flow cytometry.
Results
We observed downregulation in serum IL-6 in the 61
JIA patients with paired samples (p=0.02) pre to post
MTX (14pg/ml to 10pg/ml) and a downward trend was
also measured in JDM serum (p=0.1). Interestingly, IL1-
beta concentrations were low in JIA (<1pg/ml) but ele-
vated in JDM (50pg/ml pre and 61pg/ml post MTX).
We measured an elevated proportion of IL-17+ CD4 T
cells in JDM PBMC before therapy compared to healthy
children controls (p=0.08) that did not go back to con-
trol levels even after MTX treatment.
Conclusion
The proinflammatory cytokine blood signature appears
different in JIA and JDM patients pre-MTX therapy. For
JDM patients, the observation that higher levels in the
blood of Th17 cells which fail to reduce after treatment,
may represent a need for novel therapies which will tar-
get the Th17 pathway.
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